98 results on '"Borrow, R."'
Search Results
2. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010–2017)
3. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection
4. Lower risk of invasive meningococcal disease during pregnancy: national prospective surveillance in England, 2011–2014
5. Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants
6. Western blot study of Neisseria! antigens reactive with sera from cases and carriers of Neisseria meningitidi
7. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial
8. G54 Impact of pneumococcal conjugate vaccines on pneumococcal meningitis in england and wales, 2000 – 2016
9. A novel strategy to express different antigens from one modified vaccinia Ankara vaccine vector
10. G359(P) Childhood deaths attributable to invasive pneumococcal disease in england and wales, 2006–2014
11. Global Meningococcal Initiative: guidelines for diagnosis and confirmation of invasive meningococcal disease
12. Corrigendum to “The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent Adults” [J Infect 72 (2016) 405–438]
13. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults
14. What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience
15. Interactions of conjugate vaccines and co-administered vaccines
16. Serum bactericidal antibody assays – The role of complement in infection and immunity
17. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015
18. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
19. Variations inNeisseria meningitidiscarriage by socioeconomic status: a cross-sectional study
20. Streptococcus pneumoniae Serotype 1 Burden in the African Meningitis Belt: Exploration of Functionality in Specific Antibodies
21. MBL2 deficiency is associated with higher genomic bacterial loads during meningococcemia in young children
22. Meningococcal serogroup A and tetanus immunity two years after MenAfriVac™ introduction in Mali
23. Invasive Pneumococcal Disease, Comorbidities, and Polysaccharide Vaccine Use in Children Aged 5-15 Years in England and Wales
24. Antipneumococcal Seroprevalence and Pneumococcal Carriage During a Meningococcal Epidemic in Burkina Faso, 2006
25. Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms – A pilot study
26. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
27. Polysaccharide–protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa
28. Impact of the 7-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Infants Younger Than 90 Days in England and Wales
29. Haemophilus influenzae serotype B (Hib) seroprevalence in England and Wales in 2009
30. Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 3 P106A mutant
31. Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 1 E283AE304A mutant
32. Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 1 R106A mutant
33. Structure of the C-terminal barrel of Neisseria meningitidis FHbp Variant 2
34. Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 3 Wild type
35. An unusual transmission event of Neisseria meningitidis serogroup W135 type 2a in a healthcare setting, England, 2012
36. The Global Meningococcal Initiative (GMI): efforts to prevent and control meningococcal disease in India
37. Genetic susceptibility to invasive meningococcal disease: MBL2 structural polymorphisms revisited in a large case-control study and a systematic review
38. A cluster of four cases of meningococcal disease in a single nuclear family
39. Vaccination in paediatric patients with auto-immune rheumatic diseases: A systemic literature review for the European League against Rheumatism evidence-based recommendations
40. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases
41. Bacterial Genomic Detection Within Cerebrospinal Fluid of Patients With Meningococcal Disease Is Influenced by Microbial and Host Characteristics
42. Serum Antibody Kinetics following Nasal or Parenteral Challenge with Meningococcal Polysaccharide in Healthy Adults
43. Commentary on ‘Combined DTP‐HBV‐HIB vaccine versus separately administered DTP‐HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)’
44. Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial
45. Immunisation of immunocompromised children against pneumococcus: which vaccine should now be used?: Abstract G164 Table 1
46. Immunogenicity of a Heptavalent Conjugate Pneumococcal Vaccine Administered Concurrently with a Combination Diphtheria, Tetanus, Five-Component Acellular Pertussis, Inactivated Polio, and Haemophilus influenzae Type b Vaccine and a Meningococcal Group C Conjugate Vaccine at 2, 3, and 4 Months of Age
47. Investigation of Different Group A Immunoassays following One Dose of Meningococcal Group A Conjugate Vaccine or A/C Polysaccharide Vaccine in Adults
48. Failure of antibody response to polysaccharide antigen in treated panhypopituitary adults
49. Competitive Inhibition Flow Analysis Assay for the Non-Culture-Based Detection and Serotyping of Pneumococcal Capsular Polysaccharide
50. Failure of antibody response to polysaccharide antigen in treated adult panhypopituitary adults
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.